Dyslipidemia News and Research RSS Feed - Dyslipidemia News and Research

Dyslipidemia is a disruption in the amount of lipids in the blood.
Study suggests link between androgens, atherosclerosis and obesity in females

Study suggests link between androgens, atherosclerosis and obesity in females

While testosterone replacement therapies may be controversial in males, new research in The FASEB Journal may extend this controversy to females too. That's because research involving mice, appearing in the April 2015 issue, suggests that there is an association between low levels of androgens (which includes testosterone), and atherosclerosis and obesity in females. [More]
MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. [More]
Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

Amgen today announced that an application seeking marketing approval of Repatha (evolocumab) for the treatment of high cholesterol has been submitted for review to the Ministry of Health, Labour and Welfare in Japan. [More]
Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions. [More]
Liraglutide may help obese adults achieve weight loss

Liraglutide may help obese adults achieve weight loss

Obesity guidelines recommend an initial weight loss goal of 5 to 10% of start weight to improve health. A recent study found that patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least that level of weight loss, compared to patients on placebo who made similar lifestyle changes. [More]
Medicare Part D, adherence can help save patients with high cholesterol

Medicare Part D, adherence can help save patients with high cholesterol

According to the Centers for Disease Control and Prevention, one in three American adults has high cholesterol. For those struggling with high cholesterol, getting needed prescriptions and adhering to the prescribed treatment regimen is critical. [More]
Ninety percent of patients at risk of CHD fail to receive statins

Ninety percent of patients at risk of CHD fail to receive statins

The study, published in Current Medical Research and Opinion, provides the first ever real-world view of the treatment landscape for patients at risk of CHD[1], with a sample of two million patients. But the results paint a bleak picture of prescribing patterns with the majority not being given the potentially life saving drug. [More]
Ildong Pharmaceutical to market BELVIQ (lorcaserin HCl) for weight management in South Korea

Ildong Pharmaceutical to market BELVIQ (lorcaserin HCl) for weight management in South Korea

Arena Pharmaceuticals, Inc. today announced that Ildong Pharmaceutical Co., Ltd., has informed Arena that the Ministry of Food and Drug Safety has approved BELVIQ (lorcaserin HCl) for marketing for weight management in South Korea. Ildong will market and distribute BELVIQ in South Korea under its marketing and supply agreement with Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH. [More]
Study reveals how the brain can use fatty acids to control liver lipid production

Study reveals how the brain can use fatty acids to control liver lipid production

Ways of keeping the heart healthy has widened, with the discovery that the brain can help fight off hardening of the arteries. [More]
Upregulating heme-oxygenase with hemin helps improve pericardial adipocyte morphology, function

Upregulating heme-oxygenase with hemin helps improve pericardial adipocyte morphology, function

Scientists at the University of Saskatchewan College of Medicine, Department of Physiology, Saskatoon, Canada, led by Dr. Joseph Fomusi Ndisang have determined that upregulating heme-oxygenase with hemin improves pericardial adipocyte morphology and function. [More]
Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). [More]
FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. [More]
Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)]. [More]
Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. [More]
FDA accepts Amgen's evolocumab BLA for review

FDA accepts Amgen's evolocumab BLA for review

Amgen today announced that the U.S. Food and Drug Administration has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol. [More]

Ranbaxy obtains FDA approval to manufacture, market Fenofibrate Capsules USP, 43 mg and 130 mg

Ranbaxy Laboratories Limited announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Fenofibrate Capsules USP, 43 mg and 130 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Antara Capsules, 43 and 130 mg, respectively, of Lupin Atlantis. [More]
FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF). [More]
Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis. [More]
FDA approves Contrave extended-release tablets for chronic weight management

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. [More]
New research identifies five medical conditions that contribute to more North Carolina SUD cases

New research identifies five medical conditions that contribute to more North Carolina SUD cases

Sudden unexpected death (SUD) results from a malfunction of the heart and causes a rapid loss of blood flow through the body, leading to death. It is a very rapid process and may have few or no known warning signs. The overall survival rate for out-of-hospital arrest is only 5-10%. SUD is responsible for upwards of 450,000 people in the United States each year, with North Carolina experiencing an average of 32 SUD-related deaths each day. [More]
Advertisement
Advertisement